Background ENCORE, an observational, prospective, open‐label study, investigated real‐
world treatment practices and outcomes with cetuximab plus platinum‐based therapy (PBT) …

Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Background: The EXTREME regimen (cetuximab+ PBT≤ 6 cycles followed by cetuximab-
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …

Background: The randomized, phase 3 EXTREME study established cetuximab+ platinum+
5-flurouracil (5-FU) followed by cetuximab maintenance until progressive disease (PD) as …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

Background: The EXTREME regimen (cetuximab+ platinum+ 5-FU up to 6 cycles followed
by cetuximab maintenance until progression) is the global gold standard of care for 1L R/M …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

Background The purpose of this study was to assess the efficacy, safety, and
pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in …

5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …